Key Points
- CEO Richard Nolan Townsend sold 55,000 shares on April 6 at an average price of $5.69 for $312,950, executed under a pre‑arranged Rule 10b5‑1 plan and reducing his stake by ~13.92% to 340,106 shares (≈$1.94M).
- Lexeo is a clinical‑stage biotech with a market cap of ~$467.5M and negative earnings (analysts expect -3.14 EPS this year), and it holds a consensus Moderate Buy rating with an average price target of $18.88.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares in the company, valued at approximately $1,935,203.14. The trade was a 13.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Richard Nolan Townsend also recently made the following trade(s):
- On Wednesday, February 18th, Richard Nolan Townsend sold 10,173 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $6.38, for a total value of $64,903.74.
Lexeo Therapeutics Price Performance
NASDAQ:LXEO opened at $6.31 on Wednesday. Lexeo Therapeutics, Inc. has a 1 year low of $1.75 and a 1 year high of $10.99. The stock's 50 day simple moving average is $6.53 and its two-hundred day simple moving average is $7.98. The company has a market cap of $467.49 million, a price-to-earnings ratio of -2.88 and a beta of 1.99.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. As a group, analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.
Hedge Funds Weigh In On Lexeo Therapeutics
A number of large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. lifted its holdings in shares of Lexeo Therapeutics by 363.1% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company's stock worth $17,787,000 after buying an additional 3,469,210 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter worth $37,000. Avoro Capital Advisors LLC purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter worth $32,769,000. 683 Capital Management LLC lifted its holdings in shares of Lexeo Therapeutics by 21.4% in the 4th quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company's stock worth $11,122,000 after buying an additional 197,338 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Lexeo Therapeutics by 12.5% in the 4th quarter. UBS Group AG now owns 281,083 shares of the company's stock worth $2,791,000 after buying an additional 31,174 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on LXEO shares. Chardan Capital reissued a "buy" rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. HC Wainwright cut their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, January 13th. Raymond James Financial started coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a "strong-buy" rating and a $25.00 target price on the stock. Finally, Oppenheimer reissued an "outperform" rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $18.88.
Check Out Our Latest Analysis on Lexeo Therapeutics
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
